Prima BioMed Ltd. (PBMD) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Prima BioMed is a biotechnology company developing personalized bio-therapeutic products for cancer in Australia. The company’s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon to be in trials for additional cancer types. In addition, PBMD focuses on developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. For more information visit the company’s Web site at www.primabiomed.com.au
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
